Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $23.87 Average Price Target from Analysts

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has been assigned a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $24.17.

A number of equities research analysts have recently weighed in on the company. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 29th. JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Stifel Nicolaus raised their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Jefferies Financial Group restated a “hold” rating and set a $25.60 target price (down from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Deerfield Management Company L.P. Series C increased its stake in shares of Deciphera Pharmaceuticals by 2.8% in the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after purchasing an additional 190,580 shares during the period. Armistice Capital LLC grew its position in Deciphera Pharmaceuticals by 12.7% during the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $83,876,000 after buying an additional 588,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Deciphera Pharmaceuticals by 14.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock worth $37,220,000 after buying an additional 290,968 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Deciphera Pharmaceuticals by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock worth $25,191,000 after buying an additional 92,410 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its position in Deciphera Pharmaceuticals by 176.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock worth $16,482,000 after buying an additional 651,800 shares in the last quarter. 70.96% of the stock is currently owned by institutional investors.

Deciphera Pharmaceuticals Price Performance

NASDAQ:DCPH opened at $25.38 on Monday. The business’s 50-day moving average price is $16.56 and its 200 day moving average price is $14.80. The firm has a market cap of $2.09 billion, a P/E ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals has a 52-week low of $9.90 and a 52-week high of $25.47.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The company had revenue of $48.30 million for the quarter, compared to the consensus estimate of $45.93 million. During the same period in the previous year, the business earned ($0.60) EPS. The company’s revenue was up 32.9% on a year-over-year basis. Sell-side analysts expect that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.